A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)

In brief

This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.

Key facts

Study ID

NCT01727141

Run by

Novartis Pharmaceuticals

People needed

1042

Starts

2012-11-01

Expected to finish

2014-02-01

Last updated by the study team

2016-03-29

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients that have signed informed consent and are >/= 40 years of age.
• Patients with stable COPD according to GOLD 2011.
• Patients with a post-bronchodilator FEV1 of >/= 30% and < 80% predicted and a post-bronchodilator FEV1/FVC <0.70.
• Current or ex-smokers who have a smoking history of at least 10 pack years.
• Patients with an mMRC grade 2 or greater.

You may not qualify if…

• Patients with Type I or uncontrolled Type II diabetes - Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (>450 ms for males and females) and confirmed by a central assessor. (These patients should not be re-screened.)
• Patients who have a clinically significant ECG abnormality at Visit 101 or Visit 102. (These patients should not be re-screened.)
• Patients with a history of malignancy of any organ system, treated or untreated, within the last five years.
• Patients with narrow-angle glaucoma, BPH or bladder-neck obstruction or moderate-severe renal impairment or urinary retention.
• Patients who had a COPD exacerbation within 6 weeks prior to screening.
• Patients who have a respiratory tract infection within 4 weeks prior to screening.
• Patients requiring long term oxygen therapy prescribed for more than 12 hr per day.
• Patients with a history of asthma. 8. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to age 40 years.
• Patients with a blood eosinophil count of greater than 600 mm/3 during run-in.
• Patients with concomitant pulmonary disease.
• Patients with a diagnosis of alpha-1 anti-trypsin deficiency.
• Patients with active pulmonary tuberculosis.
• Patients in the active phase of a pulmonary rehabilitation programme.
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Montgomery, Alabama, United States
• Novartis Investigative Site — Mesa, Arizona, United States
• Novartis Investigative Site — Phoenix, Arizona, United States
• Novartis Investigative Site — Fountain Valley, California, United States
• Novartis Investigative Site — Fullerton, California, United States
• Novartis Investigative Site — Huntington Beach, California, United States
• Novartis Investigative Site — Montclair, California, United States
• Novartis Investigative Site — Orange, California, United States
• Novartis Investigative Site — Orangevale, California, United States
• Novartis Investigative Site — Paramount, California, United States
• Novartis Investigative Site — Riverside, California, United States
• Novartis Investigative Site — Roseville, California, United States
• Novartis Investigative Site — Sacramento, California, United States
• Novartis Investigative Site — Sacramento, California, United States
• Novartis Investigative Site — Sacramento, California, United States
• Novartis Investigative Site — San Diego, California, United States
• Novartis Investigative Site — Torrance, California, United States
• Novartis Investigative Site — Wheat Ridge, Colorado, United States
• Novartis Investigative Site — Waterbury, Connecticut, United States
• Novartis Investigative Site — Chiefland, Florida, United States
• Novartis Investigative Site — Clearwater, Florida, United States
• Novartis Investigative Site — Lynn Haven, Florida, United States
• Novartis Investigative Site — Savannah, Georgia, United States
• Novartis Investigative Site — Meridian, Idaho, United States
• Novartis Investigative Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.